According to a decree published Tuesday, December 10 in the Official Journal, the vaccine from the British laboratory GSK against shingles will be covered in France for the elderly and adults whose immune system is failing.
Until now, the Shingrix vaccine, recommended since March 2024 for people aged 18 and over whose immune system is failing, as well as for people aged 65 and over, was available in town pharmacies, but without being reimbursed. .
It has been reimbursed since May at 100% only at the hospital as part of a so-called direct access system, an advance treatment procedure for certain medications.
Coverage by health insurance is planned for “prevention of shingles and postherpetic neuralgia in adults 65 years and older, and adults 18 years and older at increased risk of shingles“, details the decree.
An infection due to reactivation of the varicella-zoster virus
“This step also means that community pharmacists, nurses and medical biologists will now be able to prescribe and administer Shingrix.“, underlines in a press release the GSK laboratory which markets Shingrix in more than 40 countries.
Shingles is an infection that can affect anyone who has had chickenpox. It is due to the reactivation of the varicella-zoster virus, which can occur when the immune system is weakened due to, for example, illness, treatment (such as chemotherapy) or age, according to the High Authority health (HAS).
The HAS concluded in March that “the effectiveness of the Shingrix vaccine” was “much higher than that of the Zostavax vaccine” recommended since 2013 for the elderly.
Health
